Profile
PALI NVO VRTX REGN SGEN ARGX
Company Name Palisade Bio, Inc. Novo Nordisk A/S Vertex Pharmaceuticals Incorporated Regeneron Pharmaceuticals, Inc. Seagen Inc. argenx SE
Sector Healthcare Healthcare Healthcare Healthcare Healthcare Healthcare
Industry Biotechnology Biotechnology Biotechnology Biotechnology Biotechnology Biotechnology
Market Cap $3.78M $489.27B $129.02B $89.92B $43.15B $36.03B
Employees 0.01K 69.26K 5.40K 14.17K 3.26K 1.15K
CEO Mr. J. D. Finley Mr. Lars Fruergaard Jorgensen Dr. Reshma Kewalramani FASN, M.D. Dr. Leonard S. Schleifer M.D., Ph.D. Mr. David R. Epstein B.Sc., M.B.A. Mr. Timothy Van Hauwermeiren EMBA, M.Sc.
Ratings
PALI NVO VRTX REGN SGEN ARGX
Quant Rating Score 3 3 2 4 3 2
Quant Rating Neutral Neutral Sell Buy Neutral Sell
Trading
PALI NVO VRTX REGN SGEN ARGX
Last Close $2.84 $110.13 $499.88 $829.43 $228.74 $602.47
High 52 $8.46 $146.91 $505.78 $1201.76 $228.74 $602.47
Low 52 $0.36 $102.13 $392.81 $828.84 $228.74 $356.01
Price vs. 52 Week High -66.43 % -25.04 % -1.17 % -30.98 % 0 % 0 %
Price vs. 52 Week Low 688.89 % 7.83 % 27.26 % 0.07 % 0 % 69.23 %
Total Return
PALI NVO VRTX REGN SGEN ARGX
1 Month Return -17.2 % -4.33 % 9.79 % -18.11 % 0 % 13.68 %
3 Month Return -21.33 % -15.36 % 5.4 % -22.21 % 0 % 23.71 %
6 Month Return -66.43 % -11.61 % 24.19 % -13.48 % 0 % 53 %
9 Month Return 525.69 % -6.36 % 20.13 % -11.56 % 0 % 53.25 %
YTD Return 381.36 % 6.46 % 22.85 % -5.56 % 0 % 58.37 %
1 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
3 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
5 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
Dividends
PALI NVO VRTX REGN SGEN ARGX
Dividend Yield Percentage (TTM) - 1.33 % - - - -
Dividend Paid and Capex Coverage Ration (TTM) - 1.26 % -2.62 % 4.88 % -3.35 % -2.22 %
Dividend Per Share (TTM) - 0.21 % - - - -
Payout Ratio (TTM) - 46.71 % - - - -
Growth
PALI NVO VRTX REGN SGEN ARGX
Asset Growth -10.85 % 30.35 % 25.23 % 13.23 % -1.21 % 44.93 %
Gross Profit Growth 247.31 % 32.32 % 9.25 % 6.49 % 22.93 % 190.7 %
Revenue Growth - 31.26 % 10.17 % 7.76 % 24.65 % 198.56 %
Revenue 3 Year 125 % 90.51 % 59.87 % 55.67 % 91.84 % 2074.24 %
Revenue 5 Year -96.16 % 124.2 % 218.58 % 110.3 % 215.48 % 3040.37 %
Revenue 10 Year -97.23 % 66.11 % 608.27 % 549.62 % 494.04 % 9013.37 %
EBIT Growth 18.29 % 37.11 % -12.94 % -14.6 % 10.13 % 40.94 %
Net Income Growth 3.77 % 50.71 % 8.96 % -8.87 % 9.51 % 58.42 %
Net Income 3 Yeari Growth Per Share 85.82 % 106.79 % 34.59 % 13.48 % -764.83 % 63.97 %
Net Income 5 Yeari Growth Per Share 90.01 % 133.86 % 70.33 % 74.02 % -276.93 % -143.56 %
Net Income 10 Yeari Growth Per Share 99.24 % 98.61 % 809.6 % 871.12 % -624.16 % -857.4 %
Operating Income Growth 18.29 % 37.11 % -12.94 % -14.6 % 10.13 % 40.94 %
Operating Cash Flow Growth (CFG) 16.67 % 38.06 % -14.35 % -8.39 % 9.07 % 51.28 %
Operating 3 Year CFG 71.59 % 118.29 % 9.63 % 76.95 % -148.34 % 21.62 %
Operating 5 Year CFG 94.22 % 163.51 % 174.78 % 125.17 % -195.86 % -329.48 %
Operating 10 Year CFG 98.72 % 150.92 % 6084.35 % 713.56 % -2622.09 % -1280.79 %
EPS Growth 87.62 % 52.28 % 8.33 % -8.54 % 10.81 % 60.46 %
EPS Diluted Growth 87.62 % 52.37 % 8.35 % -9.03 % 10.81 % 60.46 %
Book Value Per Share -88.34 % 29 % 25.58 % 15.03 % -9.83 % 38.53 %
Share Holder 3 Year Equity Growth Per Share 108.29 % 75.22 % 104.06 % 137.56 % 33.92 % 93.95 %
Share Holder 5 Year Equity Growth Per Share -92.53 % 121.9 % 291.14 % 219.1 % 220.81 % 318.67 %
Share Holder 10 Year Equity Growth Per Share -98.36 % 49.62 % 1030.79 % 1286.9 % 691.19 % 3655.65 %
Dividend Per Share Growth - 26.89 % - - - -
Dividend 3 Year Growth Per Share - 64.4 % - - - -
Dividend 5 Year Growth Per Share - 80.03 % - - - -
Dividend 10 Year Growth Per Share - 95.44 % - - - -
Debt Growth -8.66 % 4.74 % 44.1 % 0.06 % -23.28 % 60.95 %
Free Cash Flow Growth 16.7 % 9.17 % -16.47 % -17.11 % 3.67 % 51.98 %
Updated On 31 Dec 2023 31 Dec 2023 31 Dec 2023 31 Dec 2023 31 Dec 2022 31 Dec 2023
Profitability
PALI NVO VRTX REGN SGEN ARGX
Gross Profit Margin TTM 122.8 % 84.53 % 86.1 % 86.32 % 75.4 % 84.03 %
Return on Assets TTM -110.12 % 24.34 % -2.16 % 12.43 % -20.64 % -5.55 %
Return on Equity TTM -124.86 % 87.5 % -2.88 % 16.85 % -28.06 % -7.16 %
Return on Capital Employed TTM -149.01 % 61.51 % -1.72 % 11.85 % -29.5 % -11.19 %
Net Income Per EBT TTM 100 % 79.6 % -184.82 % 93.66 % 101.53 % 87.8 %
EBT Per Ebit TTM 94.79 % 101.17 % -82.68 % 124.1 % 93.47 % 63.04 %
EBIT Per Revenue TTM 5981.2 % 43.26 % -2.96 % 28.92 % -34.37 % -23.85 %
Cash Flow To Debt Ratio TTM -2402.98 % 202.13 % -49.48 % 157.08 % -475.96 % -428.57 %
Receivables Turnover TTM -1.95 3.88 6.06 2.27 3.64 3.07
Payables Turnover TTM 0.11 1.34 3.73 3.81 2.52 1.15
Inventory Turnover TTM - 1.1 1.37 0.63 1.07 0.99
Fixed Asset Turnover TTM -171.23 % 234.59 % 422.11 % 311.93 % 471.71 % 5457.44 %
Asset Turnover TTM -1.94 % 69.85 % 47.71 % 36.98 % 63.3 % 42.02 %
Operating Cash Flow Per Share TTM -9.84 25.87 -3.27 39.29 -2.87 -2.45
Free Cash Flow Per Share TTM -9.84 14.81 -4.51 31.25 -3.73 -3.56
Cash Per Share TTM 924.21 % 1405.52 % 2528.88 % 9062.44 % 657.5 % 5222.79 %
Operating Cash Flow Sales Ratio TTM 4834.8 % 44.7 % -7.94 % 30.67 % -23.48 % -7.22 %
Free Cash Flow Operating Cash Flow Ratio TTM 100 % 57.25 % 138.12 % 79.52 % 129.82 % 145.12 %
Cash Flow Coverage Ratios TTM -2402.98 % 202.13 % -49.48 % 157.08 % -475.96 % -428.57 %
Price To Free Cash Flows Ratio TTM -0.31 51.41 -110.86 26.62 -61.54 -170.56
Price To Operating Cash Flows Ratio TTM -0.29 29.53 -153.06 21.11 -79.67 -245.89
Price Cash Flow Ratio TTM -0.29 29.53 -153.06 21.11 -79.67 -245.89
Income Statement (TTM)
PALI NVO VRTX REGN SGEN ARGX
Revenue $0B $232.26B $9.84B $13.12B $1.96B $1.23B
Gross Profit $0B $196.5B $8.58B $11.3B $1.55B $1.11B
Gross Profit Ratio 98.4% 84.6% 87.17% 86.16% 79.1% 90.39%
EBITDA $-0.01B $112.94B $3.93B $5.13B $-0.62B $-0.22B
Net Income $-0.01B $83.68B $3.62B $3.95B $-0.61B $-0.3B
EPS Diluted -27.01 18.62 13.89 34.77 -3.3 -5.16
Balance Sheet (MRQ)
PALI NVO VRTX REGN SGEN ARGX
Long Term Debt $0B $20.53B $0.72B $2.7B $0.04B $0.02B
Total Liabilities $0B $207.93B $5.15B $7.11B $0.87B $0.44B
Total Equity $0.01B $106.56B $17.58B $25.97B $2.8B $4.1B
Total Investments $0B $17.5B $3.45B $13.51B $1.42B $1.18B
Total Debt $0B $27.01B $0.81B $2.7B $0.04B $0.02B
Total Assets $0.01B $314.49B $22.73B $33.08B $3.67B $4.54B
Cash Flow Statement (TTM)
PALI NVO VRTX REGN SGEN ARGX
Net Income $-0.01B $83.68B $3.62B $3.95B $-0.61B $-0.43B
Inventory $0B $-7.42B $-0.32B $-0.27B $-0.23B $-0.08B
Dividends Paid $0B $-31.77B $0B $0B $0B $0B
Operating Cash Flow $-0.01B $108.91B $3.54B $4.59B $-0.45B $-0.42B
Capital Expenditure $-0B $-38.9B $-0.26B $-0.93B $-0.08B $-0.04B
Related Stocks
Ticker Name Price
AADI Aadi Bioscience, Inc. 2.135
ABCL AbCellera Biologics Inc. 2.76
ABCM Abcam plc 23.99
ABEO Abeona Therapeutics Inc. 6.28
ABIO ARCA biopharma, Inc. 28.8
ABOS Acumen Pharmaceuticals, Inc. 3.214
ABSI Absci Corporation 4.14
ABUS Arbutus Biopharma Corporation 3.93
ABVC ABVC BioPharma, Inc. 0.553
ABVX Abivax SA American Depositary Shares 10.4
ACAD ACADIA Pharmaceuticals Inc. 15.79
ACER Acer Therapeutics Inc. 0.9
ACET Adicet Bio, Inc. 1.29
ACGN Aceragen, Inc. 0.3849
ACHL Achilles Therapeutics plc 1.045
ACHV Achieve Life Sciences, Inc. 5.12
ACIU AC Immune SA 3.095
ACLX Arcellx, Inc. 92.98
ACRV Acrivon Therapeutics, Inc. Common Stock 8.37
ACST Acasti Pharma Inc. 3.37
ETFs With Exposure to PALI
Ticker ETF Name Weight Percentage Price
ITOT iShares Core S&P Total U.S. Stock Market ETF 0 130.2
VXF Vanguard Extended Market Index Fund 0 196.09
VIEIX Vanguard Extended Market Index Fund Institutional Shares 0 142.03
VEXAX Vanguard Extended Market Index Fd Admiral Shs 0 142.04
VEMPX Vanguard Extended Market Index InstlPlus 0 350.5
Unlock